Premium
Platelet 5‐Hydroxytryptamine transport and storage in myeloproliferative disorders
Author(s) -
Cortellazzo Sergio,
Viero Piera,
Buczko Wlodzimierz,
Barbui Tiziano,
Gaetano Giovanni
Publication year - 1985
Publication title -
scandinavian journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0036-553X
DOI - 10.1111/j.1600-0609.1985.tb02247.x
Subject(s) - platelet , polycythaemia , 5 ht receptor , chemistry , serotonin , prostacyclin , aspirin , imipramine , pharmacology , chronic myelogenous leukemia , medicine , endocrinology , leukemia , biochemistry , receptor , pathology , alternative medicine
Platelets of patients with myeloproliferative disorders (MD) such as polycythaemia vera (PV), chronic myelogenous leukaemia (CML), idiopathic myelofibrosis (IM) and essential thrombocythaemia (ET) have been found to have low 5HT levels measured both by a fluorimetric and a liquid chromatographic assay. Km and Vmax for platelet active uptake of 3 H‐5HT were not significantly different in controls and patients. Inhibition of 5HT reuptake by imipramine or induction of moderate release by fenfluramine were not sufficient to distinguish the group of MD platelets from controls, although some patients had less of a tendency to retain intraplatelet amine. The low platelet 5HT content found in our patients seems not to be the consequence of disturbed active transport of 5HT across platelet membrane. Although defective storage of this amine within the cell is probable, the results of the present study do not rule out the possibility that platelets from MD patients undergo in vivo activation by endogenous stimuli not inhibited by aspirin. 10 d treatment with aspirin did not result in any significant rise in intraplatelet 5HT concentration.